Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
16-week open-label randomized outpatient trial of Exubera dosing strategies in type 2 diabetes
2006-007034-36Phase 4Terminated
- Sponsor
- Pfizer
- Start
- Sep 2007
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Technosphere insulin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Pfizer. Primary endpoint: Change in HbA1c from baseline after 16 weeks of treatment. Started Sep 2007; status: terminated.
02
Drugs
Technosphere insulin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-007034-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-007034-36.